Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 59

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 59
---
consideration and directed management to engage with Citi to prepare a preliminary financial analysis of STAAR to assist with the Board’s consideration of potential strategic alternatives.

On October 28, 2024, the Board held a meeting for the purpose of discussing the industry and competitive landscape, a strategy review, a
discussion of STAAR’s business plan and the October 7 Offer. At the meeting, representatives from Citi presented a preliminary illustrative financial analysis of STAAR. Representatives from Citi also reviewed other potential buyers and
the extent to which they might be interested in, and capable of, acquiring STAAR, as well as potential benefits and risks associated with soliciting interest from other potential buyers. The Board discussed STAAR’s standalone strategy,
including potential alternative revenue channels, and members of STAAR’s management reviewed certain risks and opportunities that could impact STAAR’s future

-37-

operations and expected revenue growth. Following discussion, the Board directed management to continue discussions with Alcon regarding a potential transaction and to request a formal written
proposal from Alcon, and directed management to prepare a dataroom with information to facilitate Alcon’s diligence, subject to the receipt of a written proposal.

Also, on October 28, 2024, Mr. Frinzi contacted Mr. Endicott to request a written proposal reflecting the terms on which Alcon
would be willing to proceed with a transaction.

On October 29, 2024, Mr. Endicott sent Mr. Frinzi a letter setting forth
certain terms under which Alcon proposed to acquire STAAR (the “October 29 Offer”). The October 29 Offer offered $55.00 in cash per share of STAAR common stock, plus one contingent value right per share that would pay up to $7.00
upon the achievement of certain unspecified revenue milestones. On October 29, 2024, the trading price of STAAR common stock closed at $30.29 per share.

During the period from October 29, 2024 until January 3, 2024, representatives of Alcon and its advisors conducted business and
legal due diligence, and engaged in due diligence discussions with STAAR’s management, representatives and advisors. The diligence focused on, among other things, STAAR’s commercial sales, potential synergies and risks, legal, audit and
compliance matters, human resources matters, finance and accounting matters, and STAAR’s standalone business plan, including STAAR’s expectations for its China business and the vulnerability